NYSE American: IGC

Investor Relations

Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.

SL-3-3 (2)
IGC Files Patent for Hyalolex Formulation
Read More →
SL-3-3 (2)
IGC Partners to Launch Hyalolex in Puerto Rico
Read More →
SL-3-3 (2)
IGC Appoints Carrolee Barlow, MD, PhD as Advisor to Help Develop Cannabis Related Products for Treating Various End Points of Parkinson ¢â€ž ¢s Disease and Movement Disorders (PDMD)
Read More →
SL-3-3 (2)
IGC Partners with Parkinson ¢â€ž ¢s Institute and Clinical Center to Develop Cannabis Related Products for Treating Various End Points of Parkinson ¢â€ž ¢s Disease and Movement Disorders (PDMD)
Read More →
SL-3-3 (2)
IGC Announces Third Quarter Financial Results Advances Hyalolex to Commercialization Stage
Read More →
IGC ¢â€ž ¢s CEO to Speak at CEO Healthcare Symposium in NY on February 12 & 13
Read More →
SL-3-3 (2)
IGC Reports Promising Spatial Memory Results in Alzheimer ¢â€ž ¢s Study
Read More →
SL-3-3 (2)
IGC to Use Blockchain to Address Issues Specific to the Medical Cannabis Industry
Read More →
SL-3-3 (2)
IGC Announces Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 29, 2017
Read More →